Therefore, targeting epigenetic dysregulation, particularly through DOT1L inhibition, holds promise for advancing the treatment of retinoblastoma and minimizing the long-term adverse effects associated with conventional chemotherapy. Here, DOT1L is linked to retinoblastoma.